• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SteadyMed seeks FDA nod for Trevyent drug-device combo

July 3, 2017 By Sarah Faulkner

SteadyMed TherapeuticsSteadyMed (NSDQ:STDY) said today that it submitted a new drug application to the FDA for its drug-device pulmonary arterial hypertension therapy.

The San Ramon, Calif.-based company’s lead product candidate is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.

“The submission of our NDA for Trevyent is the latest in a series of significant milestones and accomplishments for SteadyMed thus far in 2017, and we are delighted that we are one major step closer to potentially making Trevyent available to patients suffering from PAH,” president & CEO Jonathan Rigby said in prepared remarks. “PAH is a serious, life threatening disease, and currently, the administration of high dose prostacyclins to help these patients has some serious challenges. Our drug product candidate, Trevyent, has been developed with the aim of addressing these challenges and we look forward to launching it in mid 2018, subject to FDA approval.”

Cardiome Pharma Corp. (NSDQ:CRME), which licensed the commercial rights to Trevyent for some international markets in June 2015, said that it expects to file for European Medicines Agency and Health Canada approval by the end of 2017.

“The NDA filing with the FDA is an important step in the development of Trevyent, and advances us closer to our goal of bringing what we believe is a better way to deliver treprostinil to patients around the world who are suffering from PAH,” Hugues Sachot, Cardiome’s chief commercial officer, added. “Our partnership with SteadyMed continues to progress well, and we will work closely with them to file with both the EMA and Health Canada by the end of this year.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Cardiome Pharma Corp, SteadyMed Therapeutics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS